Edition:
United Kingdom

Depomed Inc (DEPO.OQ)

DEPO.OQ on NASDAQ Stock Exchange Global Select Market

6.18USD
17 Nov 2017
Change (% chg)

$-0.03 (-0.48%)
Prev Close
$6.21
Open
$6.17
Day's High
$6.27
Day's Low
$6.09
Volume
275,369
Avg. Vol
399,318
52-wk High
$21.37
52-wk Low
$4.32

Latest Key Developments (Source: Significant Developments)

Depomed announces Q3 loss of $0.25 per share
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Depomed Inc :Depomed inc sees ‍2017 total revenue $375 to $380 million​.Sees ‍2017 non-gaap adjusted ebitda $104 to $109 million​.Depomed inc sees ‍2017 non-gaap total revenue $380 to $385 million​.Q3 adjusted non-GAAP earnings per share $0.14.Q3 GAAP loss per share $0.25.Q3 revenue $95 million versus i/b/e/s view $99.1 million.Q3 earnings per share view $0.11 -- Thomson Reuters I/B/E/S.FY 2017 revenue view $396.3 million -- Thomson Reuters I/B/E/S.Company will experience temporary outages of certain strengths of nucynta er in q4​.Based on current inventory, manufacturer's potential ability to produce nucynta er supply, expect magnitude of outages to be less than $10 million​.Company believes it has an adequate inventory of gralise, which is manufactured in Puerto Rico​.Does not anticipate material disruption to nucynta ir supply from new third party manufacturer in the u.s.​.  Full Article

Depomed and Slán Medicinal Holdings announce strategic asset transactions
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Depomed Inc :Depomed and Slán Medicinal Holdings Ltd announce strategic asset transactions.Depomed Inc - ‍Slán Medicinal Holdings limited to acquire Lazanda from Depomed​.Depomed - co to buy from Slán rights to market specialty drug, cosyntropin in united states and divest its Lazanda nasal spray cii to Slán​.Depomed - intends to seek approval for cosyntropin in u.s., subsequent to approval co, Slán to share in net sales of Cosyntropin for 10-year period​.  Full Article

PDL Biopharma announces settlement agreement with Valeant
Monday, 30 Oct 2017 

Oct 30 (Reuters) - PDL Biopharma Inc :PDL Biopharma announces settlement agreement with Valeant.PDL Biopharma - ‍Valeant to pay a one-time, lump-sum payment of $13.0 million as part of settlement.PDL Biopharma - ‍Valeant's one-time, lump-sum payment will be transferred to co pursuant to terms of Depomed royalty agreement.PDL Biopharma - ‍Valeant's one-time, lump-sum payment to co will not recognized as revenue by Depomed​.PDL - ‍depomed, co to release Valeant from claims against it arising from royalty audit, Valeant's obligation to pay royalties during audit period​.PDL Biopharma Inc- ‍valeant will release Depomed, co from all claims against them as a result of audit and/or litigation​.PDL - ‍entered into settlement with Valeant that resolves matters relating to "alleged underpayment of royalties by Valeant"​.  Full Article

Depomed ‍provides information on impact of hurricane Maria to supply of NUCYNTA ER​
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - Depomed Inc : :Says ‍provides information on impact of hurricane Maria to supply of NUCYNTA ER​.Depomed Inc - ‍most recent assessment that co has received from manufacturer of NUCYNTA ER indicates that facility in Puerto Rico suffered minor damage.Depomed Inc - ‍company's Q3 product revenue was negatively impacted by approximately $2 to $3 million​ due to hurricane Maria.Depomed Inc says site leaders at facility in Puerto Rico​ are working to return facility to full operation.Depomed Inc - ‍expects its Q4 product revenue may be negatively impacted by less than $10 million​.Says ‍NUCYNTA ER is manufactured in Puerto Rico by company's third party manufacturing partner​.Depomed - ‍co will provide an update to its full year 2017 financial guidance and on NUCYNTA ER supply situation during its Q3 conference call in early November​.Depomed - ‍does not currently anticipate, based on information available to it at this time, any material disruption to supply of NUCYNTA IR or Gralise​.  Full Article

Depomed reports second quarter 2016 financial results
Wednesday, 3 Aug 2016 

Depomed Inc : Q2 adjusted non-GAAP earnings per share $0.27 . Q2 revenue $117 million versus I/B/E/S view $117.9 million . Q2 earnings per share view $0.26 -- Thomson Reuters I/B/E/S . Depomed reports second quarter 2016 financial results . Q2 loss per share $0.17 . Sees 2016 non-GAAP adjusted ebitda $175 million to $190 million . FY2016 earnings per share view $1.20, revenue view $495.0 million -- Thomson Reuters I/B/E/S . Depomed inc says depomed is updating its 2016 financial guidance .Sees 2016 total revenue $480 million to $505 million.  Full Article

Depomed- Court order extending stay in NUCYNTA ANDA litigation
Wednesday, 18 May 2016 

Depomed Inc : Depomed announces district court order extending stay in NUCYNTA ANDA litigation .Additional six months of patent protection is expected for these patents upon issuance of pediatric exclusivity from FDA.  Full Article

Depomed Inc revises FY 2016 revenue guidance
Thursday, 5 May 2016 

Depomed Inc:Revising FY 2016 financial guidance for total revenue, total non-GAAP SG&A expense and total non-GAAP R&D expense.Total Revenue $490 to $520 million (Prior Guidance $485 to $525 million).Total Non-GAAP SG&A Expense $185 to $195 million.Total Non-GAAP R&D Expense $28 to $35 million.  Full Article

Depomed Inc gives FY 2016 guidance
Monday, 22 Feb 2016 

Depomed Inc:Sees Fy 2016 Total Revenue $485 to $525 million.Sees Fy 2016 Total Non-GAAP SG&A Expense $180 to $195 million.Sees Fy 2016 Total Non-GAAP R&D Expense $30 to $40 million.Sees Fy 2016 Non-GAAP Adjusted Earnings $95 to $115 million.Sees Fy 2016 Non-GAAP Adjusted EBITDA $175 to $205 million.  Full Article

BRIEF-Depomed announces Q3 loss of $0.25 per share

* Depomed inc sees ‍2017 non-gaap total revenue $380 to $385 million​